Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 10Salivary Gland Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1HER2-Positive Primary Breast Cancer 1Glioma 1

Interventions

Fluorouracil 14Nivolumab 13Oxaliplatin 12Leucovorin 11Paclitaxel 7Capecitabine 7pembrolizumab 6Radiotherapy 5Cisplatin 5Taxes 4Specimen Handling 4Radiation 4Irinotecan 4Drug Therapy 4dehydroftorafur 3Trastuzumab 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2futibatinib 2Levoleucovorin 2Endoscopy, Digestive System 2Endoscopy 2Carboplatin 2Biopsy 2zolbetuximab 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Ado-Trastuzumab Emtansine × 90 days × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡